Bausch + Lomb Corp logo

BLCOBausch + Lomb Corp

NYSE · Healthcare · Medical Instruments & Supplies

$18.37

+$0.49 (+2.74%)

Bausch + Lomb Corp (BLCO) is a medical instruments & supplies company listed on NYSE. It is led by Brenton L. Saunders J.D., based in 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4, with about 13,000 employees. Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

Latest reported BLCO revenue for 2025-09-30 was $1.28B. Net income was -$25.0M. Revenue was up 0.2% from 2025-06-30 to 2025-09-30. BLCO currently screens at market cap $5.38B.

Use this BLCO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BLCO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BLCO SEC filings page. Lician reads the product cache first so this HTML stays unique to Bausch + Lomb Corp even when a live quote feed is slow.

About Bausch + Lomb Corp

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

BLCO Key Statistics

Market Cap

$5.38B

Volume

449,704

Previous Close

$17.32

Day Range

$17.00$17.44

0

P/B Ratio

0.84

EPS

-$0.90

Revenue

$4.79B

Net Income

-$305.00M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

+15.6%

Profit Margin

-6.4%

Employees

13,000

BLCO Financials

Annual income statement in USD. Latest reported periods first.

BLCO annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$4.79B$4.15B$3.77B$3.77B
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$305.00M-$248.00M$15.00M$193.00M
EPS (Diluted)-$0.90-$0.74$0.02$0.52

Total Assets

$13.47B

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$305.00M

Operating Cash Flow

$232.00M

Free Cash Flow

$0.00

Bausch + Lomb Corp Company Information

CEO & Chairman
Brenton L. Saunders J.D.
Headquarters
520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4
Phone
905 695 7700
IPO / Founded
2022-05-06
Industry
Medical Instruments & Supplies
Data Updated:

Upcoming Events for BLCO